AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 894653 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane stripping
Number of subjects: 91
Study 28128982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 96
Study 28128982 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil (a wakefulness promoting agent)
Number of subjects: 96
Study 28128982 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 96
Study 28687496 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab 210mg QM
Number of subjects: 252
Study 28687496 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab 70mg QM
Number of subjects: 252
Study 28687496 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab 140mg QM
Number of subjects: 252
Study 28687496 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab (all doses)
Number of subjects: 252
Study 28687496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 26010952 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) - 40 sessions, 5 days/week, 90 minutes, 100% oxygen at 2ATA
Number of subjects: 60
Study 26010952 — intervention group
Group type: COMPARATOR
Intervention: Control period (no treatment)
Number of subjects: 60
Study 23124582 — intervention group
Group type: EXPERIMENTAL
Intervention: Test messages
Number of subjects: 2020
Study 23124582 — intervention group
Group type: COMPARATOR
Intervention: Control message
Number of subjects: 2020
Study 21787045 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 176
Study 21787045 — intervention group
Group type: COMPARATOR
Intervention: Individual therapy (IT)
Number of subjects: 176
Study 19420918 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily
Number of subjects: 227
Study 19420918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 16958717 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal breastfeeding workshop
Number of subjects: 110
Study 16958717 — intervention group
Group type: COMPARATOR
Intervention: Control group (no workshop)
Number of subjects: 110
Study 15238993 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)-linalool
Number of subjects: 14
Study 15238993 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 14
Study 10590454 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 50
Study 9132194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal diamorphine (0.1 mg/kg)
Number of subjects: 58
Study 9132194 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine (0.2 mg/kg)
Number of subjects: 58
Study 9132194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal diamorphine
Number of subjects: 58
Study 9132194 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 58
Study 9132194 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 58
Study 8140393 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐Fluoro‐Uracil + leucovorin
Number of subjects: 16
Study 8140393 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐Fluoro‐Uracil + interferon alpha‐2‐a
Number of subjects: 16
Study 8140393 — intervention group
Group type: COMPARATOR
Intervention: 5‐Fluoro‐Uracil + leucovorin or 5‐Fluoro‐Uracil + interferon alpha‐2‐a
Number of subjects: 16
Study 3539046 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg of ivermectin in a single dose
Number of subjects: 59
Study 3539046 — intervention group
Group type: EXPERIMENTAL
Intervention: 1300 mg of diethylcarbamazine over eight days
Number of subjects: 59
Study 3539046 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo capsules
Number of subjects: 59
Study 29846976 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (every 2 weeks or 4 weeks)
Number of subjects: 3126
Study 29846976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3126
Study 30250339 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose del Nido cardioplegia (DNC)
Number of subjects: 30
Study 30250339 — intervention group
Group type: COMPARATOR
Intervention: Multidose conventional blood cardioplegia (CBC)
Number of subjects: 30
Study 26539964 — intervention group
Group type: EXPERIMENTAL
Intervention: Galectin-3
Number of subjects: 401
Study 26539964 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopontin
Number of subjects: 401
Study 26539964 — intervention group
Group type: EXPERIMENTAL
Intervention: Gremlin-1
Number of subjects: 401
Study 25272531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (3mg/kg)
Number of subjects: 182
Study 25272531 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (0.1mg/kg)
Number of subjects: 182
Study 22458722 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse researchers engaging in clinical research communication
Number of subjects: 0
Study 20624281 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive laparotomy with temporary abdominal closure
Number of subjects: 100
Study 20624281 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous puncture with placement of abdominal catheter
Number of subjects: 100
Study 17983374 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM avoidance intervention
Number of subjects: 0
Study 17983374 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15863546 — intervention group
Group type: EXPERIMENTAL
Intervention: E+P (0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate)
Number of subjects: 16608
Study 11873001 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotypic resistance testing (PRT)
Number of subjects: 272
Study 11873001 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 272
Study 9462523 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate (5-MTHF)
Number of subjects: 10
Study 9462523 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (matched, N=10)
Number of subjects: 10
Study 7622762 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol 200 micrograms four times daily
Number of subjects: 11
Study 7622762 — intervention group
Group type: COMPARATOR
Intervention: Placebo 2 puffs four times daily
Number of subjects: 11
Study 2709673 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 kcal/kg desirable body weight/day
Number of subjects: 6
Study 2709673 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 kcal/kg desirable body weight/day
Number of subjects: 6
Study 2709673 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 kcal/kg desirable body weight/day
Number of subjects: 6
Study 334607 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated phenylbutazone (Butacote)
Number of subjects: 50
Study 334607 — intervention group
Group type: COMPARATOR
Intervention: Standard phenylbutazone (Butazolidine)
Number of subjects: 50
Study 30741360 — intervention group
Group type: EXPERIMENTAL
Intervention: Zio XT Monitor (ZM)
Number of subjects: 21
Study 30741360 — intervention group
Group type: EXPERIMENTAL
Intervention: NUUBO Vest (NV)
Number of subjects: 21
Study 30741360 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnation Ambulatory Monitor (CAM)
Number of subjects: 21
Study 30741360 — intervention group
Group type: COMPARATOR
Intervention: RT (Novacor 'R' Test 4)
Number of subjects: 21
Study 30930074 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-ESD
Number of subjects: 91
Study 30930074 — intervention group
Group type: COMPARATOR
Intervention: S-ESD
Number of subjects: 91
Study 27925235 — intervention group
Group type: EXPERIMENTAL
Intervention: MiECC
Number of subjects: 150
Study 27925235 — intervention group
Group type: COMPARATOR
Intervention: cCPB
Number of subjects: 150
Study 25516008 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction to approach fictitious social groups (Niffites and Luupites)
Number of subjects: 0
Study 25516008 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction to avoid fictitious social groups (Niffites and Luupites)
Number of subjects: 0
Study 25516008 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction to approach well-known social groups (Blacks and Whites)
Number of subjects: 0
Study 25516008 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction to avoid well-known social groups (Blacks and Whites)
Number of subjects: 0
Study 24087909 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized working memory training (Cogmed QM)
Number of subjects: 47
Study 24087909 — intervention group
Group type: COMPARATOR
Intervention: Integrated rehabilitation (Control Group)
Number of subjects: 47
Study 24087909 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IG and CG)
Number of subjects: 47
Study 21366432 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation similar to currently used protocols
Number of subjects: 0
Study 21366432 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cooling and nutritional intervention
Number of subjects: 0
Study 21366432 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 19478715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic injection of prednisolone
Number of subjects: 79
Study 19478715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic injection of dexamethasone
Number of subjects: 79
Study 19478715 — intervention group
Group type: COMPARATOR
Intervention: Oral carbamazepine
Number of subjects: 79
Study 16750449 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg BID
Number of subjects: 181
Study 16750449 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg BID
Number of subjects: 181
Study 16750449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 15221569 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention including discectomy and fusion on one or two levels with cage, plate, and screws; corpectomy in severe cases; combined approach with dorsal decompression and ventral fusion in one case.
Number of subjects: 16
Study 15221569 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 16
Study 11693321 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication therapy + omeprazole 40 mg once daily for 12 months
Number of subjects: 71
Study 11693321 — intervention group
Group type: COMPARATOR
Intervention: H. pylori persistent group
Number of subjects: 71
Study 11693321 — intervention group
Group type: COMPARATOR
Intervention: H. pylori negative group
Number of subjects: 71
Study 9926054 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive community treatment
Number of subjects: 0
Study 9926054 — intervention group
Group type: COMPARATOR
Intervention: Standard community treatment
Number of subjects: 0
Study 7941938 — intervention group
Group type: EXPERIMENTAL
Intervention: suxamethonium
Number of subjects: 54
Study 7941938 — intervention group
Group type: COMPARATOR
Intervention: vecuronium
Number of subjects: 54
Study 2836059 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. melphalan with concomitant oral misonidazole
Number of subjects: 100
Study 2836059 — intervention group
Group type: COMPARATOR
Intervention: i.v. melphalan
Number of subjects: 100
Study 31886700 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message interventions
Number of subjects: 296
Study 29710726 — intervention group
Group type: EXPERIMENTAL
Intervention: ADD-continuation group (N=30)
Number of subjects: 65
Study 29710726 — intervention group
Group type: COMPARATOR
Intervention: ADD-discontinuation group (N=35)
Number of subjects: 65
Study 27183075 — intervention group
Group type: EXPERIMENTAL
Intervention: Microthreaded coronal aspect implants (Hexplant)
Number of subjects: 54
Study 27183075 — intervention group
Group type: EXPERIMENTAL
Intervention: Rough-surface implants (Brånemark)
Number of subjects: 54
Study 27183075 — intervention group
Group type: EXPERIMENTAL
Intervention: Machined coronal aspect implants (Restore)
Number of subjects: 54
Study 26092063 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg per day
Number of subjects: 1637
Study 26092063 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 40 μg per day
Number of subjects: 1637
Study 26092063 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 or 40 μg per day combined)
Number of subjects: 1637
Study 26092063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1637
Study 23780370 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cold exposure at 19 °C
Number of subjects: 31
Study 20936540 — intervention group
Group type: EXPERIMENTAL
Intervention: Remune and ALVAC
Number of subjects: 49
Study 19050299 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1-specific Abs induced by vaccination (U.S.)
Number of subjects: 0
Study 19050299 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1-specific Abs induced by natural infection (Mali)
Number of subjects: 0
Study 19050299 — intervention group
Group type: COMPARATOR
Intervention: Mali-non-AMA1 IgG
Number of subjects: 0
Study 19050299 — intervention group
Group type: COMPARATOR
Intervention: U.S.-non-AMA1 IgGs
Number of subjects: 0
Study 19050299 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1-based vaccines
Number of subjects: 0
Study 16880017 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment of MTBI
Number of subjects: 191
Study 16880017 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment (control)
Number of subjects: 191
Study 14652301 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline waist circumference
Number of subjects: 2739
Study 14652301 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline body mass index (BMI)
Number of subjects: 2739
Study 14652301 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight and waist circumference cycling
Number of subjects: 2739
Study 10946987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative PAR Corneal Topography System (IOPAR)
Number of subjects: 26
Study 10946987 — intervention group
Group type: COMPARATOR
Intervention: Slit lamp PAR CTS
Number of subjects: 26
Study 10946987 — intervention group
Group type: COMPARATOR
Intervention: EyeSys Corneal Analysis System (EyeSys CAS)
Number of subjects: 26
Study 10946987 — intervention group
Group type: COMPARATOR
Intervention: Manual keratometer (Mnl‐Km)
Number of subjects: 26
Study 10946987 — intervention group
Group type: COMPARATOR
Intervention: Autokeratometer (Auto‐Km)
Number of subjects: 26
Study 8869671 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 24
Study 8869671 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg kg‐1
Number of subjects: 24
Study 1892362 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dipyridamole, 75 mg, and acetylsalicylic acid, 330 mg, three times a day
Number of subjects: 2500
Study 1892362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study 1892362 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dipyridamole and acetylsalicylic acid
Number of subjects: 2500
Study 6367366 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol (Omnipaque)
Number of subjects: 88
Study 30284700 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% FIT039 patch
Number of subjects: 10
Study 30284700 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% FIT039 patch
Number of subjects: 10
Study 30284700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 27480628 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chest computed tomography (LDCT)
Number of subjects: 232
Study 27266803 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard tangents (STs) or high tangents (HTs) for micrometastatic SLNs without lymphovascular system invasion, used by 115 (87.1%) respondents.
Number of subjects: 145
Study 27266803 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard tangents (STs) and supraclavicular field (SCF) or STs and full axillary coverage (AX) without neoadjuvant chemotherapy (NAC), used by 64 (48.5%) respondents.
Number of subjects: 145
Study 27266803 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular field (SCF) and full axillary coverage (AX) after neoadjuvant chemotherapy (NAC), used by 94 (70.7%) respondents.
Number of subjects: 145
Study 27266803 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular field (SCF) for macrometastatic SLN involvement, preferred by 45.27% of respondents.
Number of subjects: 145
Study 27266803 — intervention group
Group type: EXPERIMENTAL
Intervention: Full axillary coverage (AX) for macrometastatic SLN involvement, preferred by 45.66% of respondents.
Number of subjects: 145
Study 27266803 — intervention group
Group type: EXPERIMENTAL
Intervention: High tangents (HTs) for micrometastatic involvement, chosen by 43.61% of respondents.
Number of subjects: 145
Study 27266803 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of online predictive nomograms to predict further axillary involvement, reported by 40 (27.8%) respondents.
Number of subjects: 145
Study 24731898 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AA) using auricular plasters with magnetic pellets
Number of subjects: 99
Study 24731898 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled group (AA using auricular plasters with Semen Vaccariae)
Number of subjects: 99
Study 24731898 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (AA using auricular plasters only)
Number of subjects: 99
Study 22105826 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and capecitabine followed by cyclophosphamide, epirubicin, and capecitabine (TX/CEX)
Number of subjects: 1500
Study 22105826 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel followed by cyclophosphamide, epirubicin, and fluorouracil (T/CEF)
Number of subjects: 1500
Study 21305906 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute marijuana use
Number of subjects: 70
Study 21305906 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 70
Study 17437876 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation using fluted files for 3 minutes
Number of subjects: 85
Study 17437876 — intervention group
Group type: COMPARATOR
Intervention: Passive ultrasonic irrigation using nonfluted finger spreaders for 1 minute
Number of subjects: 85
Study 17437876 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation using fluted files for 1 minute
Number of subjects: 85
Study 17437876 — intervention group
Group type: COMPARATOR
Intervention: Passive ultrasonic irrigation using nonfluted finger spreaders
Number of subjects: 85
Study 15561737 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg subcutaneously twice weekly
Number of subjects: 26
Study 15561737 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 26
Study 17058761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar-clip attachments
Number of subjects: 18
Study 17058761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball-socket attachments
Number of subjects: 18
Study 17058761 — intervention group
Group type: COMPARATOR
Intervention: Magnet attachments
Number of subjects: 18
Study 17058761 — intervention group
Group type: COMPARATOR
Intervention: New lower denture without attachments
Number of subjects: 18
Study 17058761 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction on VAS
Number of subjects: 18
Study 17058761 — intervention group
Group type: COMPARATOR
Intervention: Maximum bite force
Number of subjects: 18
Study 10877193 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) infusion (5 mg/kg BW priming bolus and 0.025, 0.1, or 1.0 mg/kg BW/min constant infusion)
Number of subjects: 18
Study 10877193 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) infusion
Number of subjects: 18
Study 10877193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8896005 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL/kg of 0.25% bupivacaine with 1:200,000 epinephrine at a rate of 1 mL/s (subgroup A)
Number of subjects: 79
Study 8896005 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL/kg of 0.25% bupivacaine with 1:200,000 epinephrine at a rate of 1 mL per 10 s (subgroup B)
Number of subjects: 79
Study 1999752 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutorial + Prompt
Number of subjects: 261
Study 1999752 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutorial Only
Number of subjects: 261
Study 1999752 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt Only
Number of subjects: 261
Study 1999752 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 261
Study 1999752 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutorial + Prompt, Tutorial Only, Prompt Only
Number of subjects: 261
Study 6644094 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA + visible radiation
Number of subjects: 0
Study 6644094 — intervention group
Group type: COMPARATOR
Intervention: Visible light alone
Number of subjects: 0
Study 30720443 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐ADM
Number of subjects: 28
Study 30720443 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 28836462 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-anchor repair technique
Number of subjects: 9
Study 28836462 — intervention group
Group type: COMPARATOR
Intervention: Control group (no repair)
Number of subjects: 9
Study 25970541 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra‐epidermal electrical stimulation (IES)
Number of subjects: 196
Study 24242191 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgery
Number of subjects: 100
Study 24242191 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic technique
Number of subjects: 100
Study 22726802 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily for 7 days
Number of subjects: 248
Study 22726802 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily for 14 days
Number of subjects: 248
Study 21044308 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 28
Study 21044308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 21044308 — intervention group
Group type: COMPARATOR
Intervention: Healthy non-AR controls
Number of subjects: 28